EA200401586A1 - Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста - Google Patents

Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста

Info

Publication number
EA200401586A1
EA200401586A1 EA200401586A EA200401586A EA200401586A1 EA 200401586 A1 EA200401586 A1 EA 200401586A1 EA 200401586 A EA200401586 A EA 200401586A EA 200401586 A EA200401586 A EA 200401586A EA 200401586 A1 EA200401586 A1 EA 200401586A1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin
growth hormone
salt
metal
compositions
Prior art date
Application number
EA200401586A
Other languages
English (en)
Other versions
EA010548B1 (ru
Inventor
Мишал Хамид Ал-Сари
Original Assignee
Инсайнион Холдингз Лимитед
Веритрон Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайнион Холдингз Лимитед, Веритрон Лимитед filed Critical Инсайнион Холдингз Лимитед
Publication of EA200401586A1 publication Critical patent/EA200401586A1/ru
Publication of EA010548B1 publication Critical patent/EA010548B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)

Abstract

Композиция, характеризующаяся различным терапевтическим и косметическим применением, включает (i) витамин; (ii) соль металла, которая предоставляет in vivo ионы металла; и (iii) инсулин или гормон роста. Такую композицию можно использовать для лечения, например, генетических нарушений, кожных заболеваний, злокачественных опухолей и вирусных инфекций.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401586A 2002-05-29 2003-05-27 Применение композиции витамина с и соли кальция для лечения рака EA010548B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212405.5A GB0212405D0 (en) 2002-05-29 2002-05-29 Composition and its therapeutic use
PCT/GB2003/002295 WO2003101479A1 (en) 2002-05-29 2003-05-27 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone

Publications (2)

Publication Number Publication Date
EA200401586A1 true EA200401586A1 (ru) 2005-04-28
EA010548B1 EA010548B1 (ru) 2008-10-30

Family

ID=9937661

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401586A EA010548B1 (ru) 2002-05-29 2003-05-27 Применение композиции витамина с и соли кальция для лечения рака

Country Status (30)

Country Link
EP (2) EP1513546A1 (ru)
JP (3) JP4362441B2 (ru)
CN (3) CN1655811A (ru)
AP (1) AP2004003177A0 (ru)
AR (1) AR039895A1 (ru)
AT (1) ATE468134T1 (ru)
AU (4) AU2003236893A1 (ru)
BR (1) BR0311371A (ru)
CA (1) CA2487678A1 (ru)
DE (1) DE60332578D1 (ru)
EA (1) EA010548B1 (ru)
EC (1) ECSP045458A (ru)
GB (3) GB0212405D0 (ru)
IL (1) IL164952A0 (ru)
IS (1) IS7578A (ru)
MA (1) MA27207A1 (ru)
ME (1) MEP22908A (ru)
MX (1) MXPA04011794A (ru)
MY (2) MY139933A (ru)
NO (1) NO20044768L (ru)
NZ (1) NZ536360A (ru)
OA (1) OA12862A (ru)
PL (1) PL374199A1 (ru)
RS (1) RS102304A (ru)
SM (1) SM200300009A (ru)
TN (1) TNSN04235A1 (ru)
TW (1) TW200425892A (ru)
UY (1) UY27827A1 (ru)
WO (1) WO2003101479A1 (ru)
ZA (2) ZA200210316B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
GB0501654D0 (en) * 2005-01-26 2005-03-02 Veritron Ltd Stabilised plant extract
GB0523257D0 (en) * 2005-11-15 2005-12-21 Veritron Ltd Purification process
GB0710536D0 (en) 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
DE102007030103A1 (de) * 2007-06-28 2009-01-02 Bode Chemie Gmbh & Co. Kg Verwendung einer synergistischen Zusammensetzung als therapeutisches oder kosmetisches Mittel
GB0808974D0 (en) * 2008-05-16 2008-06-25 Veritron Ltd Plant extract and its therapeutic use
EP2420228A1 (en) 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
JP5756326B2 (ja) * 2011-04-14 2015-07-29 一丸ファルコス株式会社 キネシン抑制剤
WO2013119061A1 (ko) * 2012-02-07 2013-08-15 포항공과대학교 산학협력단 경피 전달용 히알루론산-단백질 컨쥬게이트의 제조 방법 및 이에 따라 제조된 경피 전달용 히알루론산-단백질 컨쥬게이트
CN105722500B (zh) * 2013-09-11 2019-08-30 伊戈尔生物药品股份有限公司 包含离子性液体的液体蛋白质制剂
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
FR3057773B1 (fr) 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
CA3194304A1 (en) * 2020-09-30 2022-04-07 Reven Pharmaceuticals Inc. Pharmaceutical compositions and methods for prevention and/or treatment of inflammation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
FR2126134A1 (en) * 1971-02-26 1972-10-06 Ates Ibrahim Cyclophosphamide/magnesium compsns - with enhanced cytostatic activity
JPH02144075A (ja) * 1988-11-25 1990-06-01 Olympus Optical Co Ltd 薬剤放出装置
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
JP2902886B2 (ja) * 1992-12-28 1999-06-07 三洋電機株式会社 記録ディスク演奏装置
CA2112539A1 (en) * 1993-12-29 1995-06-30 Romualdo D. Candelario Medicated herbal lotion
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
EP0802257B1 (fr) * 1996-04-19 2002-08-21 Societe Des Produits Nestle S.A. Lignée immortalisée de cellules épithéliales du colon humain
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
JP2000086510A (ja) * 1998-09-16 2000-03-28 Oriza Yuka Kk ヒスタミン遊離抑制剤
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
CA2375647A1 (en) * 1999-07-08 2001-01-18 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
NZ511396A (en) * 1999-08-30 2003-08-29 Oxycal Lab Inc Compositions containing a metal salt of ascorbic acid for selective cancer chemotherapy
AU779798C (en) * 1999-11-15 2005-11-17 Hanamaraddi T. Gangal Dextrose and insulin fluid formulation for intravenous infusion
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
WO2001064211A1 (fr) * 2000-03-03 2001-09-07 Lee Shu Wen Médicament spécifique pour le traitement du sida
DK1195159T3 (da) * 2000-10-09 2006-10-02 Matthias Dr Med Rath Terapeutisk kombination af ascorbat med lysin og arginin til forebyggelse eller behandling af cancer
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use

Also Published As

Publication number Publication date
AU2003204391A1 (en) 2003-12-18
DE60332578D1 (de) 2010-07-01
PL374199A1 (en) 2005-10-03
AU2007203159A1 (en) 2007-07-26
UY27827A1 (es) 2003-12-31
RS102304A (en) 2006-12-15
GB0325839D0 (en) 2003-12-10
MY134288A (en) 2007-11-30
BR0311371A (pt) 2005-04-05
CN1466994A (zh) 2004-01-14
ECSP045458A (es) 2005-05-30
NO20044768L (no) 2005-02-24
AU2007203159B2 (en) 2009-03-26
EP1366768B1 (en) 2010-05-19
AU2003236893A1 (en) 2003-12-19
AU2003204391B2 (en) 2005-08-04
GB0615918D0 (en) 2006-09-20
OA12862A (en) 2006-09-15
ZA200409551B (en) 2005-10-11
TW200425892A (en) 2004-12-01
EP1513546A1 (en) 2005-03-16
EA010548B1 (ru) 2008-10-30
AR039895A1 (es) 2005-03-09
EP1366768A1 (en) 2003-12-03
CN101380463A (zh) 2009-03-11
AU2009200893A1 (en) 2009-04-09
GB2427824A (en) 2007-01-10
IS7578A (is) 2004-12-01
TNSN04235A1 (en) 2007-03-12
SM200300009B (it) 2004-12-01
ATE468134T1 (de) 2010-06-15
CN1655811A (zh) 2005-08-17
MA27207A1 (fr) 2005-01-03
WO2003101479A1 (en) 2003-12-11
MY139933A (en) 2009-11-30
JP2009143947A (ja) 2009-07-02
JP2006500324A (ja) 2006-01-05
GB2392618A (en) 2004-03-10
IL164952A0 (en) 2005-12-18
MEP22908A (en) 2010-06-10
SM200300009A (it) 2004-12-01
JP2004002429A (ja) 2004-01-08
GB2392618B (en) 2007-02-21
ZA200210316B (en) 2003-07-04
GB0212405D0 (en) 2002-07-10
NZ536360A (en) 2008-03-28
AP2004003177A0 (en) 2004-12-31
CA2487678A1 (en) 2003-12-11
JP4362441B2 (ja) 2009-11-11
MXPA04011794A (es) 2005-07-05

Similar Documents

Publication Publication Date Title
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MXPA05007822A (es) Terapia de combinacion para tratar trastornos de la deficiencia de proteinas.
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
EA200600750A1 (ru) Трансдермальная фармацевтическая композиция
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200700493A1 (ru) Новое применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
HK1205531A1 (en) Mesenchymal stem cells and uses therefor
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
BRPI0418157A (pt) terapêutica de tumores alogênicos
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU